{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 57,
  "pageCount": 105,
  "prevPage": 56,
  "nextPage": 58,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/57",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-57",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Clinical strategy in place to enable accelerated approval: Monotherapy (MYD88MT DLBCL for most direct path to registration; Other MYD88MT lymphomas of interest include PCNSL, WM) Combinations (With SOC agents in MYD88MT DLBCL to enable earlier line therapy)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fc055bc-1fd8-420b-a71c-3fddd57e6c2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Profound antitumor activity in preclinical models both in single agent and combination",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c943be41-244c-4f1f-83ed-5b0806813646",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "IRAKIMiD Degrader KT-413 has Potential to be First Precision Medicine in DLBCL to Target a Genetically-defined Population (MYD88MT)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10baea2b-8c28-4ef0-94f7-6f5cedf33e50",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "d72c8243-c8ac-4333-b021-5efd69b61bca",
      "evidence": "list/bullet: Clinical strategy in place to enable accelerated approval: Monotherapy (MYD88MT DLBCL for most direct path to registration; Other MYD88MT lymphomas of interest include PCNSL, WM) Combinations (With SOC agent",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}